Asked by: Liz Jarvis (Liberal Democrat - Eastleigh)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the UK-US Pharmaceutical deal on patient access to medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom has secured mitigations under the United States’ ‘Most Favoured Nation’ drug pricing initiative so that we will continue to ensure access to the latest treatments. This will encourage pharmaceutical companies from around the world to prioritise the UK for early launches of their new medicines, getting new treatments to the National Health Service frontline faster and securing our access to and supply of medicines for patients all across the NHS.
The agreement will see the NHS invest approximately 25% more in innovative treatments, the first major increase in over two decades, meaning patients will now be able to access cutting-edge therapies that may have otherwise been deemed not cost-effective. This could include breakthrough cancer treatments, therapies for rare diseases, and innovative approaches to conditions that have long been difficult to treat.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department are taking to ensure the effectiveness of cancer screening programmes in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Screening and Immunisation Teams, including a dedicated team covering Thames Valley, work closely with providers and local partners to ensure cancer screening programmes are delivered in line with national standards for quality, safety and effectiveness.
At a local level, the NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board (ICB) works in partnership with NHS England, primary care, providers and the Thames Valley Cancer Alliance to support the delivery and uptake of cancer screening programmes across Buckingham and Bletchley. This includes ongoing monitoring of screening coverage and performance at place and practice level, identifying variation, and supporting action where uptake or performance falls below national standards.
At a national level, we recently announced that the NHS Bowel Cancer Screening Programme in England is lowering the faecal immunochemical test threshold from 120 micrograms of blood per gram of faeces to 80 micrograms of blood per gram of faeces. It is estimated that this change will detect approximately 600 additional bowel cancers early each year in England, approximately an 11% increase, and find 2,000 more people with high-risk polyps in their bowel, allowing doctors to remove them before they ever turn into cancers.
Additionally, in early 2026, the NHS Cervical Screening Programme will be offering a self-testing kit to under-screened women, starting with those who are the most overdue for screening. This will help tackle deeply entrenched barriers that keep some away from screening.
These national-level changes will benefit people across England, including those living in the Buckingham and Bletchley constituency.
Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 January 2026 to Question 106495, what assessment has been made of the reasons for the 25% reduction in the numbers of those aged 75 and over self referring for bowel cancer screening between 2023 and 2024.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services is a priority for the Government. We will get the National Health Service diagnosing cancer earlier and treating it faster so that more patients survive, and we will improve patients’ experience across the system.
The bowel cancer screening programme primarily focuses on uptake and coverage of those eligible for screening, those aged 50 to 74 years old, and how these individuals progress through the pathway for additional diagnostic tests where required. As those over 75 years old self-referring fall outside the primary cohort no analysis has been made of the fluctuations in numbers.
Over 75s can still ask for a kit every two years by phoning the free bowel cancer screening helpline. Anyone experiencing symptoms is encouraged to seek medical advice immediately.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what safeguards exist to prevent patients from losing access to established, life-extending cancer treatments as a result of changes to NICE methodology.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) evaluates all newly licensed cancer medicines and may recommend promising treatments for use through the Cancer Drugs Fund (CDF) where there is too much clinical uncertainty for routine commissioning. Under these arrangements, cancer medicines are made available to National Health Service patients for a defined period while further real‑world evidence is collected to address the uncertainties identified in NICE’s original appraisal.
At the end of the managed access period, NICE undertakes a full re‑appraisal of the medicine. This re‑appraisal considers all the evidence gathered during CDF use alongside updated clinical and cost‑effectiveness analyses. NICE then determines whether the medicine should be routinely funded by the NHS, or whether it cannot be recommended for routine commissioning. This re‑appraisal process is one of the limited circumstances in which NICE routinely re‑evaluates previous decisions.
In 2022, NICE updated its methods and replaced the earlier end‑of‑life flexibilities with the severity modifier. As a result, re‑appraisals of cancer medicines that originally entered the CDF under end‑of‑life criteria are now conducted in line with NICE’s current methods framework, ensuring consistency, fairness, and opportunity‑cost neutrality across all appraisals. NICE has recommended 96% of the medicines that it has re-appraised following a period of managed access for routine NHS use. Where NICE is unable to recommend a medicine for routine use following the period of managed access, it remains available for existing patients but is no longer routinely funded for new patients.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact on patients of withdrawing access to an existing cancer treatment, namely CAR-T therapy for relapsed or refractory mantle cell lymphoma, which has been available on the NHS since 2021.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
202 patients have received brexucabtagene autoleucel, a form of CAR-T therapy, for the treatment of mantle cell lymphoma via the Cancer Drugs Fund (CDF). This data is taken from NHS England’s prior approval system. The National Institute for Health and Care Excellence (NICE) is currently re-evaluating the evidence on clinical outcomes collected through its use in the CDF in its ongoing re-evaluation of brexucabtagene autoleucel.
NICE published final draft guidance on 24 December 2025 in which it was not able to recommend brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had two or more lines of systemic treatment that included a Bruton's tyrosine kinase inhibitor. This is because the extent of brexucabtagene autoleucel’s clinical benefit is uncertain. There are also uncertainties in the economic model because there is not enough evidence to tell if the cancer can be ‘cured’ in people having brexucabtagene autoleucel and it is not known how long people live after having brexucabtagene autoleucel. The cost-effectiveness estimates are also substantially above the range that NICE considers an acceptable use of National Health Service resources. NICE has not yet published final guidance and stakeholders have recently had an opportunity to appeal NICE’s recommendations.
The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many patients have received CAR-T therapy for mantle cell lymphoma via the Cancer Drugs Fund; and what assessment has been made of the clinical outcomes for those patients.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
202 patients have received brexucabtagene autoleucel, a form of CAR-T therapy, for the treatment of mantle cell lymphoma via the Cancer Drugs Fund (CDF). This data is taken from NHS England’s prior approval system. The National Institute for Health and Care Excellence (NICE) is currently re-evaluating the evidence on clinical outcomes collected through its use in the CDF in its ongoing re-evaluation of brexucabtagene autoleucel.
NICE published final draft guidance on 24 December 2025 in which it was not able to recommend brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had two or more lines of systemic treatment that included a Bruton's tyrosine kinase inhibitor. This is because the extent of brexucabtagene autoleucel’s clinical benefit is uncertain. There are also uncertainties in the economic model because there is not enough evidence to tell if the cancer can be ‘cured’ in people having brexucabtagene autoleucel and it is not known how long people live after having brexucabtagene autoleucel. The cost-effectiveness estimates are also substantially above the range that NICE considers an acceptable use of National Health Service resources. NICE has not yet published final guidance and stakeholders have recently had an opportunity to appeal NICE’s recommendations.
The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
Asked by: Fabian Hamilton (Labour - Leeds North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the report published by Breast Cancer Now, entitled Setting the Bar too High, what assessment his Department has made of the impact of the opportunity cost‑neutrality requirement within NICE’s severity modifier on access to treatments for secondary breast cancer.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The severity modifier was introduced by the National Institute for Health and Care Excellence (NICE) in January 2022 as part of a number of changes intended to make its methods fairer, faster, and more consistent. The severity modifier was designed on the principle of opportunity cost neutrality to ensure that introducing additional weighting for severe conditions did not increase overall National Health Service spending or displace more care than the previous end-of-life modifier.
NICE has been monitoring how the severity modifier is being applied and found that it has resulted in a greater proportion of medicines recommended than under NICE’s previous methods. The latest figures indicate 87.0% of decisions taken since the severity modifier was implemented have recommended use of the treatment, compared with 82.5% when the end-of-life modifier was being used. For advanced cancer treatments specifically, 84.8% of decisions have been positive since the introduction of the severity modifier, compared to 69.1% under NICE’s previous methods.
Asked by: Joe Robertson (Conservative - Isle of Wight East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much additional funding has been allocated in the current financial year to expand secondary care capacity, including staffing and bed numbers.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Spending Review 2025 has prioritised health, with an increase by £29 billion in real terms by 2028/29 compared to 2023/24, including investment in urgent and emergency care and electives services to deliver the 10-Year Health Plan. The plan includes the shift from hospital to community to bring care closer to home, launching a new neighbourhood health service with easier and more convenient access to a full range of healthcare services on people’s doorsteps, open 12 hours a day, six days a week.
Integrated care board (ICB) revenue allocations for 2025/26 include a total of circa £5.3 billion elective recovery funding to allow the National Health Service to continue to deliver the high levels of elective activity performance seen last year, and to deliver our Plan for Change commitments including care closer to the community. This figure includes funding for cancer services.
Over £6 billion in additional capital will be invested in diagnostic, elective, and urgent and emergency capacity in the NHS over five years, including £1.65 billion in 2025/26 to deliver new surgical hubs, diagnostic scanners and beds to increase capacity for elective and emergency care.
Decisions on staffing and bed numbers are for individual NHS organisations to decide when developing their operational plans in response to the Medium Term Planning Framework 2026/27 to 2028/29.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what estimate has been made of the annual cost to the NHS of expanding access to abiraterone; what savings have been achieved through the availability of generic versions of the drug; and how value for money will be assessed over the course of the commissioning policy.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what assessment has been made of existing regional variation in access to prostate cancer treatments and what steps are being taken to prevent disparities in uptake between different NHS trusts and integrated care boards.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.